BPTES
Based on 63 publication(s) in Google Scholar
BPTES is an allosteric and selective glutaminase inhibitor with an IC50 of 0.16 μM.
For research use only. We do not sell to patients.
- Purity: 98.04%
- CAS No.: 314045-39-1
- Formula: C24H24N6O2S3
- Molecular Weight:524.68
-
Storage:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 1 year , -20°C, 6 months
Publications Citing Use of MedChemExpress (MCE) BPTES
More- Nature. 2026 Apr;652(8112):1339-1348. [Abstract]
- Nature. 2024 Oct;634(8036):1229-1237. [Abstract]
- Cell. 2025 Dec 24;188(26):7481-7494.e16. [Abstract]
- Cancer Discov. 2026 Apr 7. [Abstract]
- J Hepatol. 2020 May;72(5):909-923. [Abstract]
- Cell Metab. 2022 Nov 1;34(11):1843-1859.e11. [Abstract]
- Nat Commun. 2026 Jan 31;17(1):2227. [Abstract]
- Nat Commun. 2025 Nov 24;16(1):10322. [Abstract]
- Nat Commun. 2025 May 15;16(1):4502. [Abstract]
- Bone Res. 2025 Jun 12;13(1):62. [Abstract]
- Autophagy. 2025 Jan;21(1):80-101. [Abstract]
- Adv Sci (Weinh). 2026 Apr;13(21):e13341. [Abstract]
- Theranostics. 2020 May 16;10(14):6483-6499. [Abstract]
- Sci Adv. 2025 Aug 29;11(35):eadu6271. [Abstract]
- Brain. 2024 Aug 28:awae270. [Abstract]
- Nano Today. 2023 Dec, 53, 102009.
- Mater Today Bio. 2025 Feb 25:31:101608. [Abstract]
- Mater Today Bio. 2023 Feb 15:19:100577. [Abstract]
- Cell Death Dis. 2025 Feb 6;16(1):72. [Abstract]
- Acta Biomater. 2023 Aug:166:470-484. [Abstract]
- Acta Biomater. 2023 Mar 1:158:560-570. [Abstract]
- Cell Death Dis. 2022 Mar 11;13(3):229. [Abstract]
- Cell Death Dis. 2021 Oct 20;12(11):975. [Abstract]
- Phytomedicine. 2024 Nov 8:135:156223. [Abstract]
- Phytomedicine. 2024 Jul 25:133:155906. [Abstract]
- Clin Sci. 2025 Oct 22;139(20):1163-1185. [Abstract]
- PLoS Biol. 2026 Mar 12;24(3):e3003698. [Abstract]
- Aging Cell. 2026 Mar;25(3):e70434. [Abstract]
- Cell Rep. 2026 Apr 25;45(5):117297. [Abstract]
- Cell Rep. 2023 Jun 6;42(6):112617. [Abstract]
- J Agric Food Chem. 2025 Sep 3;73(35):21932-21946. [Abstract]
- J Agric Food Chem. 2024 Jun 12;72(23):13039-13053. [Abstract]
- Cell Mol Life Sci. 2022 Nov 30;79(12):611. [Abstract]
- Front Immunol. 2022 Sep 20;13:977235. [Abstract]
- Biochem Pharmacol. 2025 Jun 26:240:117089. [Abstract]
- Cell Prolif. 2025 Apr 21:e70036. [Abstract]
- World J Gastroenterol. 2025 Aug 28;31(32):108654. [Abstract]
- Geroscience. 2024 Aug;46(4):3581-3597. [Abstract]
- Cancer Metab. 2025 Jun 23;13(1):33. [Abstract]
- Cancer Metab. 2025 Mar 31;13(1):16. [Abstract]
- Mbio. 2022 Jun 28;e0127422. [Abstract]
- Int Immunopharmacol. 2020 Aug;85:106664. [Abstract]
- FASEB J. 2023 Apr;37(4):e22880. [Abstract]
- J Chromatogr A. 2022 Dec 20:1686:463654. [Abstract]
- Eur J Immunol. 2025 Dec;55(12):e70087. [Abstract]
- Expert Rev Clin Immunol. 2025 Jun 25:1-11. [Abstract]
- Am J Pathol. 2025 Jul;195(7):1340-1357. [Abstract]
- Mol Hum Reprod. 2020 Feb 29;26(2):88-100. [Abstract]
- Immun Inflamm Dis. 2024 Nov;12(11):e70073. [Abstract]
- Cell Biochem Biophys. 2024 May 24. [Abstract]
- Theriogenology. 2024 Jul 15:223:1-10. [Abstract]
- Biochem Biophys Res Commun. 2026 Mar 19:805:153392. [Abstract]
- Curr Med Sci. 2024 Aug;44(4):799-808. [Abstract]
- bioRxiv. 2026 Jan 26.
- Research Square Print. 2025 May 28.
- bioRxiv. 2024 July 05.
- University of Maryland. 2024.
- Research Square Preprint. 2023 Jul 10.
- Research Square Preprint. 2023 Mar 29.
- Research Square Preprint. 2023 Apr 6.
- Research Square Print. 2022 Jun.
- bioRxiv. January 11, 2022.
- University of North Carolina at Chapel Hill. 2021 Jul.
-
WB
-
Flow Cytometry
-
2D/3D Cell Culture and Differentiation
-
2D/3D Cell Culture and Differentiation
-
WB
Biological Activity
Glutaminase[1]
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| A549 | IC50 |
0.42 μM
Compound: BPTES
|
Antiproliferative activity against human A549 cells after 5 days by EZMTT reagent-based assay
Antiproliferative activity against human A549 cells after 5 days by EZMTT reagent-based assay
|
[PMID: 30543285] |
| A549 | IC50 |
276 nM
Compound: 2, BPTES
|
Antiproliferative activity against human A549 cells assessed as reduction in cell viability measured after 72 hrs by celltiter-fluor assay
Antiproliferative activity against human A549 cells assessed as reduction in cell viability measured after 72 hrs by celltiter-fluor assay
|
[PMID: 33118821] |
| A549 | IC50 |
49 μM
Compound: BPTES
|
Antiproliferative activity against human A549 cells assessed as reduction in cell viability
Antiproliferative activity against human A549 cells assessed as reduction in cell viability
|
[PMID: 36055003] |
| ASPC1 | IC50 |
10.2 μM
Compound: BPTES
|
Growth inhibition of human Aspc-1 cells after 72 hrs by MTS assay
Growth inhibition of human Aspc-1 cells after 72 hrs by MTS assay
|
[PMID: 28609101] |
| CAKI-1 | IC50 |
1.16 μM
Compound: BPTES
|
Antiproliferative activity against human Caki1 cells after 5 days by EZMTT reagent-based assay
Antiproliferative activity against human Caki1 cells after 5 days by EZMTT reagent-based assay
|
[PMID: 30543285] |
| H22 | IC50 |
>10 μM
Compound: BPTES
|
Antiproliferative activity against mouse H22 cells after 5 days by EZMTT reagent-based assay
Antiproliferative activity against mouse H22 cells after 5 days by EZMTT reagent-based assay
|
[PMID: 30543285] |
| HCC827 | IC50 |
42.4 μM
Compound: BPTES
|
Cytotoxicity against human erlotinib-resistant HCC827 cells assessed as growth inhibition after 48 hrs by CCK8 assay
Cytotoxicity against human erlotinib-resistant HCC827 cells assessed as growth inhibition after 48 hrs by CCK8 assay
|
[PMID: 28174105] |
| HCT-116 | IC50 |
0.54 μM
Compound: BPTES
|
Antiproliferative activity against human HCT116 cells after 5 days by EZMTT reagent-based assay
Antiproliferative activity against human HCT116 cells after 5 days by EZMTT reagent-based assay
|
[PMID: 30543285] |
| HCT-116 | IC50 |
1.02 μM
Compound: BPTES
|
Antiproliferative activity against human HCT116 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
Antiproliferative activity against human HCT116 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
|
[PMID: 31603674] |
| HCT-116 | IC50 |
3.91 μM
Compound: BPTES; I-3
|
Antiproliferative activity against human HCT116 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
Antiproliferative activity against human HCT116 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
|
[PMID: 33792311] |
| HCT-116 | IC50 |
44 μM
Compound: BPTES
|
Antiproliferative activity against human HCT-116 cells assessed as reduction in cell viability
Antiproliferative activity against human HCT-116 cells assessed as reduction in cell viability
|
[PMID: 36055003] |
| HT-1080 | IC50 |
47.72 μM
Compound: BPTES
|
Cytotoxicity against human HT1080 cells assessed as growth inhibition after 48 hrs by CCK8 assay
Cytotoxicity against human HT1080 cells assessed as growth inhibition after 48 hrs by CCK8 assay
|
[PMID: 28174105] |
| MDA-MB-231 | IC50 |
2610 nM
Compound: BPTES
|
Cytotoxicity against human MDA-MB-231 cells measured on 6th day by hemocytometry
Cytotoxicity against human MDA-MB-231 cells measured on 6th day by hemocytometry
|
[PMID: 26988803] |
| MDA-MB-231 | IC50 |
6.8 μM
Compound: BPTES
|
Growth inhibition of human MDA-MB-231 cells after 72 hrs by MTS assay
Growth inhibition of human MDA-MB-231 cells after 72 hrs by MTS assay
|
[PMID: 28609101] |
| MDA-MB-231 | IC50 |
9.08 μM
Compound: BPTES
|
Antiproliferative activity against human MDA-MB-231 cells after 24 hrs by MTT assay
Antiproliferative activity against human MDA-MB-231 cells after 24 hrs by MTT assay
|
[PMID: 33176943] |
| MDA-MB-436 | IC50 |
2.4 μM
Compound: BPTES
|
Antiproliferative activity against human MDA-MB-436 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
Antiproliferative activity against human MDA-MB-436 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
|
[PMID: 31603674] |
| MDA-MB-436 | IC50 |
5.08 μM
Compound: BPTES; I-3
|
Antiproliferative activity against human MDA-MB-436 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
Antiproliferative activity against human MDA-MB-436 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
|
[PMID: 33792311] |
| NCI-H1703 | GI50 |
1.3 μM
Compound: 3; BPTES
|
Antiproliferative activity against human NCI-H1703 cells assessed as reduction in cell growth after 5 days by SYTOX green staining-based assay
Antiproliferative activity against human NCI-H1703 cells assessed as reduction in cell growth after 5 days by SYTOX green staining-based assay
|
[PMID: 31199640] |
| SW1990 | IC50 |
35.33 μM
Compound: 1; BPTES
|
Antiproliferative activity against human SW1990 cells assessed as reduction in cell viability measured after 72 hrs by CCK-8 assay
Antiproliferative activity against human SW1990 cells assessed as reduction in cell viability measured after 72 hrs by CCK-8 assay
|
[PMID: 36996714] |
BPTES (10 μM) exhibits inhibition of PDAC cell proliferation[1]. BPTES preferentially slows growth of mutant IDH1 cells without inducing apoptosis. BPTES (10 μM) reduces glutaminase activity in both WT and mutant IDH1 expressing cells, diminishes glutamate and α-KG levels, and increases glycolytic intermediates while leaving total 2-HG levels unaffected[2]. BPTES (10 μM) shows a clear synergistic anti-cancer effect with 10 μM of 5-FU in A549 and EKVX cell lines, and results in a growth reduction response not only in EKVX and A549 but also in most of the NSCLC cell lines[3]. BPTES (10 μM) effectively reduces the levels of the metabolites of the TCA cycle, with no changes in the levels of metabolites in glycolysis and the pentose phosphate pathway. BPTES treatment reduces about 30% ATP production under normoxia, and an additional 10% reduction of ATP production is observed under hypoxia in EKVX[4].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Chemical Information
-
CAS No. 314045-39-1
-
Appearance Solid
-
Molecular Weight 524.68
-
Formula C24H24N6O2S3
-
Color White to off-white
-
SMILES
O=C(NC1=NN=C(CCSCCC2=NN=C(NC(CC3=CC=CC=C3)=O)S2)S1)CC4=CC=CC=C4
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Powder -20°C 3 years 4°C 2 years In solvent -80°C 1 year -20°C 6 months
Publications (63)
-
Journal Impact Factor
-
Most Recent
-
Nature
2026 Apr;652(8112):1339-1348. PMID: 41813904 -
Nature
2024 Oct;634(8036):1229-1237. PMID: 39322678 -
Cell
Gut-to-brain signaling restricts dietary protein intake during recovery from catabolic states. [Abstract]2025 Dec 24;188(26):7481-7494.e16. PMID: 41192423 -
Cancer Discov
Correcting Mitochondrial Complex I Defect in Tumor-Associated Natural Killer Cells Potentiates Immunotherapy for Glioblastoma. [Abstract]2026 Apr 7. PMID: 41944586 -
J Hepatol
2020 May;72(5):909-923. PMID: 31899205 -
Cell Metab
2022 Nov 1;34(11):1843-1859.e11. PMID: 36103895
BPTES purchased from MedChemExpress. Usage Cited in: Cell Metab. 2022 Nov 1;34(11):1843-1859.e11. [Abstract]
BPTES treatment (3 μM, 55 min) reduced the maximal and spare respiratory capacity of Kcnj2f/f tumor-associated macrophages.
-
Nat Commun
Microbiota-induced EI24 improves homeostasis but impedes function of alveolar macrophages via metabolic regulation. [Abstract]2026 Jan 31;17(1):2227. PMID: 41620436 -
Nat Commun
2025 Nov 24;16(1):10322. PMID: 41285771 -
Nat Commun
TIGIT deficiency promotes autoreactive CD4+ T-cell responses through a metabolic‒epigenetic mechanism in autoimmune myositis. [Abstract]2025 May 15;16(1):4502. PMID: 40374622
BPTES purchased from MedChemExpress. Usage Cited in: Nat Commun. 2025 May 15;16(1):4502. [Abstract]
BPTES (3 μM, 3 days) had no effect on ACLY expression and H3K27 and H3K9 acetylation in patient CD4+ T cells.
BPTES purchased from MedChemExpress. Usage Cited in: Nat Commun. 2025 May 15;16(1):4502. [Abstract]
BPTES (3 μM, 48 h) did not reverse the increase in IFNγ, T-bet, IL-17A, and RORγt expression in Tigit−/− CD4+ T cells cultured under Th1- or Th17-polarizing conditions.
-
Bone Res
Chaperone-mediated autophagy directs a dual mechanism to balance premature senescence and senolysis to prevent intervertebral disc degeneration. [Abstract]2025 Jun 12;13(1):62. PMID: 40506462 -
Autophagy
MANF facilitates breast cancer cell survival under glucose-starvation conditions via prkn-mediated mitophagy regulation. [Abstract]2025 Jan;21(1):80-101. PMID: 39147386 -
Adv Sci (Weinh)
Single-Mitochondrion ATP Profiling Directs Discovery of Targetable OXPHOS Dependency in Cancers. [Abstract]2026 Apr;13(21):e13341. PMID: 41684301 -
Theranostics
STIM1 is a metabolic checkpoint regulating the invasion and metastasis of hepatocellular carcinoma. [Abstract]2020 May 16;10(14):6483-6499. PMID: 32483465 -
Sci Adv
Glutamate utilization fuels rapid production of mitochondrial ROS in dendritic cells and drives systemic inflammation during tularemia. [Abstract]2025 Aug 29;11(35):eadu6271. PMID: 40880474 -
Brain
2024 Aug 28:awae270. PMID: 39197036 -
-
Mater Today Bio
Nutrient transporter-oriented nanoinhibitor counteracts intracellular metabolic reprogramming for RT-resistant HCC treatment. [Abstract]2025 Feb 25:31:101608. PMID: 40104639
BPTES purchased from MedChemExpress. Usage Cited in: Mater Today Bio. 2025 Feb 25:31:101608. [Abstract]
BPTES (0-160μM, 24 h (left) and 48 h (right)) combined with RT (4Gy) inhibited cell growth in HepG2 cells.
-
Mater Today Bio
A photodynamic-mediated glutamine metabolic intervention nanodrug for triple negative breast cancer therapy. [Abstract]2023 Feb 15:19:100577. PMID: 36846308 -
Cell Death Dis
Blimp-1 orchestrates macrophage polarization and metabolic homeostasis via purine biosynthesis in sepsis. [Abstract]2025 Feb 6;16(1):72. PMID: 39915460 -
Acta Biomater
pH-Sensitive Tumor-Tropism Hybrid Membrane-Coated Nanoparticles for Reprogramming the Tumor Microenvironment and Boosting the Antitumor Immunity. [Abstract]2023 Aug:166:470-484. PMID: 37253416 -
Acta Biomater
Glutamine Metabolism Targeting Liposomes for Synergistic Chemosensitization and Starvation Therapy in Ovarian Cancer. [Abstract]2023 Mar 1:158:560-570. PMID: 36596434 -
Cell Death Dis
2022 Mar 11;13(3):229. PMID: 35277475 -
Cell Death Dis
2021 Oct 20;12(11):975. PMID: 34671029 -
Phytomedicine
Ginsenoside compound K restrains hepatic fibrotic response by dual-inhibition of GLS1 and LDHA. [Abstract]2024 Nov 8:135:156223. PMID: 39561660 -
Phytomedicine
Gegen Qinlian Decoction reverses oxaliplatin resistance in colorectal cancer by inhibiting YTHDF1-regulated m6A modification of GLS1. [Abstract]2024 Jul 25:133:155906. PMID: 39089089 -
Clin Sci
Glutamine alleviates immunosuppression in polymicrobial sepsis by augmenting bacterial phagocytosis through sustaining the GFAT-DRP1 dependent mitochondrial calcium dynamics. [Abstract]2025 Oct 22;139(20):1163-1185. PMID: 41082631 -
PLoS Biol
USP7 facilitates brain tumor survival upon glucose deprivation by regulating phosphofructokinase muscle-type nuclear translocation in mice. [Abstract]2026 Mar 12;24(3):e3003698. PMID: 41818193 -
Aging Cell
Decreased Glucose Metabolism and Declined Chaperones Are Unique Features Required for the Survival of Senescent Fibroblasts and Pyruvate Dehydrogenase Is a Potent Senolytic Target. [Abstract]2026 Mar;25(3):e70434. PMID: 41786630 -
Cell Rep
SEPHS2 loss reprograms cancer metabolism from oxidative phosphorylation to gluconeogenesis via PCK1 stabilization. [Abstract]2026 Apr 25;45(5):117297. PMID: 42035418 -
Cell Rep
Resolvin D1 reprograms energy metabolism to promote microglia to phagocytize neutrophils after ischemic stroke. [Abstract]2023 Jun 6;42(6):112617. PMID: 37285269 -
J Agric Food Chem
Hesperetin Protects from Palmitic-Acid-Induced Lipotoxicity through the Inhibition of Glutaminolysis, mTORC1 Signaling, and Limited Apoptosis. [Abstract]2025 Sep 3;73(35):21932-21946. PMID: 40838694 -
J Agric Food Chem
Elevated PINK1/Parkin-Dependent Mitophagy and Boosted Mitochondrial Function Mediate Protection of HepG2 Cells from Excess Palmitic Acid by Hesperetin. [Abstract]2024 Jun 12;72(23):13039-13053. PMID: 38809522 -
Cell Mol Life Sci
An active glutamine/α-ketoglutarate/HIF-1α axis prevents pregnancy loss by triggering decidual IGF1+GDF15+NK cell differentiation. [Abstract]2022 Nov 30;79(12):611. PMID: 36449080 -
Front Immunol
Proline metabolism reprogramming of trained macrophages induced by early respiratory infection combined with allergen sensitization contributes to development of allergic asthma in childhood of mice. [Abstract]2022 Sep 20;13:977235. PMID: 36211408 -
Biochem Pharmacol
Ghrelin attenuates metabolic dysfunction-associated steatotic liver disease by activating glutamine metabolism via inhibition of the IRE1α-XBP-1 pathway. [Abstract]2025 Jun 26:240:117089. PMID: 40581331 -
Cell Prolif
Glutaminase-1 Mediated Glutaminolysis to Glutathione Synthesis Maintains Redox Homeostasis and Modulates Ferroptosis Sensitivity in Cancer Cells. [Abstract]2025 Apr 21:e70036. PMID: 40259435 -
World J Gastroenterol
Melatonin-induced ferroptosis in pancreatic cancer cells by stimulating endoplasmic reticulum stress and inhibiting alanine-serine-cysteine transporter 2-driven glutamine metabolism. [Abstract]2025 Aug 28;31(32):108654. PMID: 40900769 -
Geroscience
Cell-free ascites from ovarian cancer patients induces Warburg metabolism and cell proliferation through TGFβ-ERK signaling. [Abstract]2024 Aug;46(4):3581-3597. PMID: 38196068 -
Cancer Metab
Dexmedetomidine promotes colorectal cancer progression mediated by gamma-aminobutyric acid signaling. [Abstract]2025 Jun 23;13(1):33. PMID: 40551256 -
Cancer Metab
Unveiling the powerhouse: ASCL1-driven small cell lung cancer is characterized by higher numbers of mitochondria and enhanced oxidative phosphorylation. [Abstract]2025 Mar 31;13(1):16. PMID: 40165271 -
Mbio
Glutamine Is Required for M1-like Polarization of Macrophages in Response to Mycobacterium tuberculosis Infection. [Abstract]2022 Jun 28;e0127422. PMID: 35762591 -
Int Immunopharmacol
2020 Aug;85:106664. PMID: 32521490
BPTES purchased from MedChemExpress. Usage Cited in: Int Immunopharmacol. 2020 Aug;85:106664. [Abstract]
BPTES/CB839 could efficiently and specifically inhibit the NLRP1b inflammsome signaling pathway in J774A.1 cells. The cell lysate is analyzed by immunoblotting using anti-Caspase-1 and anti-GAPDH antibodies.
-
FASEB J
Deletion of the tyrosine phosphatase Shp2 in cervical cancer cells promotes reprogramming of glutamine metabolism. [Abstract]2023 Apr;37(4):e22880. PMID: 36943407 -
J Chromatogr A
Targeted profiling of polar metabolites in cancer metabolic reprogramming by hydrophilic interaction liquid chromatography-tandem mass spectrometry. [Abstract]2022 Dec 20:1686:463654. PMID: 36434830 -
Eur J Immunol
Hyperinflammation by Human Macrophages Induced by SARS-CoV-2 Anti-Spike IgG Is Dependent on Glucose and Fatty Acid Metabolism. [Abstract]2025 Dec;55(12):e70087. PMID: 41416928 -
Expert Rev Clin Immunol
TFDP1 activates SPC25-mediated glutamine metabolism to repress anti-tumor immunity of NK cells in lung adenocarcinoma. [Abstract]2025 Jun 25:1-11. PMID: 40552366 -
Am J Pathol
Transcription Factor YY2 Inhibits Tumor Cell Glutamine Catabolism by Regulating GLS1 RNA Splicing Isoform GAC. [Abstract]2025 Jul;195(7):1340-1357. PMID: 40311755 -
Mol Hum Reprod
Excess palmitate induces decidual stromal cell apoptosis via the TLR4/JNK/NF-kB pathways and possibly through glutamine oxidation. [Abstract]2020 Feb 29;26(2):88-100. PMID: 31977025 -
Immun Inflamm Dis
Formoterol Reduces the Pro-Inflammatory Phenotype by Enhancing the Activity of Glutaminase in Monocyte-Derived Macrophages in the CVB3-Induced Viral Myocarditis. [Abstract]2024 Nov;12(11):e70073. PMID: 39601476 -
Cell Biochem Biophys
AGC1-mediated Metabolic Reprogramming and Autophagy Sustain Survival of Hepatocellular Carcinoma Cells under Glutamine Deprivation. [Abstract]2024 May 24. PMID: 38789662 -
Theriogenology
Glutamate rescues heat stress-induced apoptosis of Sertoli cells by enhancing the activity of antioxidant enzymes and activating the Trx1-Akt pathway in vitro. [Abstract]2024 Jul 15:223:1-10. PMID: 38642435 -
Biochem Biophys Res Commun
Proline metabolism supports the hepatocellular carcinoma cell survival by mitigating ROS generation under nutrient starvation. [Abstract]2026 Mar 19:805:153392. PMID: 41650851 -
Curr Med Sci
2024 Aug;44(4):799-808. PMID: 39096478 -
-
-
-
-
-
-
-
-
-
Solvent & Solubility
DMSO : 25 mg/mL (47.65 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 1 year; -20°C, 6 months. When stored at -80°C, please use it within 1 year. When stored at -20°C, please use it within 6 months.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 1 year; -20°C, 6 months. When stored at -80°C, please use it within 1 year. When stored at -20°C, please use it within 6 months.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: 2.5 mg/mL (4.76 mM); Suspended solution; Need ultrasonic
This protocol yields a suspended solution of 2.5 mg/mL. Suspended solution can be used for oral and intraperitoneal injection.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Protocol
Cells are plated at a density of 500 cells/well in a 96-well black clear bottom plate. At 24 hrs, media is changed to the appropriate media (DMEM with 4.5 g/L, 1.5 g/L or 0.1 g/L glucose, 10% FBS, and 4 mM glutamine). 48 hours after plating, compounds or DMSO are added. Media and alamarBlue is added to a volume of 200 µL in each well. Fluorescence is measured at 48 hrs or 72 hrs (EGCG) using a Victor3 plate-reader.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Four-week-old female Foxn1nuathymic nude mice are used for the assay. Freshly resected pancreatic tumor samples obtained from patients at the time of surgery are propagated from mouse to mouse as a live tumor bank. Once a tumor volume of 50 mm3 is reached (4 wk postimplantation), mice are treated with 12.5 mg/kg BPTES by intraperitoneal injection, 200 mg/kg CB-839 twice per d by oral gavage, 54 mg/kg BPTES-NPs (1.2 mg BPTES in 100 µL nanoparticles per mouse) by intravenous injection, blank-NPs (100 µL per mouse) by intravenous injection, 25 mg/kg LY 188011 intraperitoneally, or a combination of BPTES-NPs with LY 188011. BPTES-NPs are injected once every 3 d for a total of six injections over 16 d.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Purity & Documentation
-
Data Sheet (277 KB)
-
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
-
Handling Instructions (2659 KB)
References
[1]. Elgogary A, et al. Combination therapy with BPTES nanoparticles and targets the metabolic heterogeneity of pancreatic cancer. Proc Natl Acad Sci U S A. 2016 Sep 6;113(36):E5328-36. [Content Brief]
[2]. Meghan J. Seltzer, et al. Inhibition of glutaminase preferentially slows growth of glioma cells with mutant IDH1. Cancer Res. 2010 Nov 15; 70(22): 8981-8987. [Content Brief]
[3]. Lee JS, et al. Glutaminase 1 inhibition reduces thymidine synthesis in NSCLC. Biochem Biophys Res Commun. 2016 Aug 26;477(3):374-82 [Content Brief]
[4]. Lee JS, et al. Dual targeting of glutaminase 1 and thymidylate synthase elicits death synergistically in NSCLC. Cell Death Dis. 2016 Dec 8;7(12):e2511. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 1 year; -20°C, 6 months. When stored at -80°C, please use it within 1 year. When stored at -20°C, please use it within 6 months.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 1.9059 mL | 9.5296 mL | 19.0592 mL | 47.6481 mL |
| 5 mM | 0.3812 mL | 1.9059 mL | 3.8118 mL | 9.5296 mL | |
| 10 mM | 0.1906 mL | 0.9530 mL | 1.9059 mL | 4.7648 mL | |
| 15 mM | 0.1271 mL | 0.6353 mL | 1.2706 mL | 3.1765 mL | |
| 20 mM | 0.0953 mL | 0.4765 mL | 0.9530 mL | 2.3824 mL | |
| 25 mM | 0.0762 mL | 0.3812 mL | 0.7624 mL | 1.9059 mL | |
| 30 mM | 0.0635 mL | 0.3177 mL | 0.6353 mL | 1.5883 mL | |
| 40 mM | 0.0476 mL | 0.2382 mL | 0.4765 mL | 1.1912 mL |